NMDA antagonists under investigation for the treatment of major depressive disorder

Expert Opinion on Investigational Drugs

Volumn 23, Issue 9, 2014, Pages 1181-1192

  Pochwat, Bartłomiej ^a   Pałucha Poniewiera, Agnieszka ^a   Szewczyk, Bernadeta ^a   Pilc, Andrzej ^a,b   Nowak, Gabriel ^a,b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antagonists; Antidepressant; Channel; Glycine site; NMDA receptor

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 7 CHLOROKYNRENIC ACID; AMANTADINE; AMPA RECEPTOR AGONIST; ANTIDEPRESSANT AGENT; AZD 6755; CYCLOSERINE; DEXTRO SERINE; DIZOCILPINE; FLUOXETINE; GLUTAMIC ACID; GLYX 13; IMIPRAMINE; KETAMINE; LAMOTRIGINE; LANICEMINE; MEMANTINE; MK 0657; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N [2 [4 (3 THIENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; PHENCYCLIDINE; REBOXETINE; RECEPTOR SUBUNIT; RILUZOLE; RO 6325; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; AMINO ACID RECEPTOR STIMULATING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ABSENCE OF SIDE EFFECTS; ANTIDEPRESSANT ACTIVITY; BIPOLAR DISORDER; DEPRESSION; DISSOCIATIVE DISORDER; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HALLUCINATION; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; NONHUMAN; RECEPTOR AFFINITY; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPRESSIVE DISORDER, MAJOR; DRUG DESIGN; DRUG RESISTANCE; PATHOPHYSIOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG DESIGN; DRUG RESISTANCE; EXCITATORY AMINO ACID AGONISTS; HUMANS; KETAMINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84906068528     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.918951     Document Type: Review

References (97)

1. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21(9):655-79
2. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53(8):649-59
3. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry 2006;67(Suppl 6):16-22
4. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999;375(1-3):31-40
5. Szewczyk B, Palucha-Poniewiera A, Poleszak E, et al. Investigational NMDA receptor modulators for depression. Expert Opin Investig Drugs 2012;21(1):91-102
6. Pilc A, Wieronska JM, Skolnick P. Glutamate-based antidepressants: Preclinical psychopharmacology. Biol Psychiatry 2013;73(12):1125-32
7. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992;258(5082):597-603
8. Niciu MJ, Henter ID, Luckenbaugh DA, et al. Glutamate receptor antagonists as fast-Acting therapeutic alternatives for the treatment of depression: Ketamine and other compounds. Annu Rev Pharmacol Toxicol 2014;54:119-39
9. Lau CG, Takeuchi K, Rodenas-Ruano A, et al. Regulation of NMDA receptor Ca2 + signalling and synaptic plasticity. Biochem Soc Trans 2009;37(6):1369-74
10. Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: Diversity, development and disease. Curr Opin Neurobiol 2001;11(3):327-35
11. K€ohr G. NMDA receptor function: Subunit composition versus spatial distribution. Cell Tissue Res 2006;326(2):439-46
12. Parsons CG, Quack G, Bresink I, et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 1995;34(10):1239-58
13. Mealing GAR, Lanthorn TH, Murray CL, et al. Differences in degree of trapping of low-Affinity uncompetitive N-methyl-D-Aspartic acid receptor antagonists with similar kinetics of block. J Pharmacol Exp Ther 1999;288(1):204-10
14. Williams K. Extracellular modulation of NMDA receptors. In: Van Dongen AM, editor. Biology of the NMDA receptor. CRC Press, Boca Raton, FL; 2009. Chatper 11
15. Skolnick P, Layer RT, Popik P, et al. Adaptation of N-methyl-D-Aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996;29(1):23-6
16. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185(1):1-10
17. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009;30(11):563-9
18. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47(4):351-4
19. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: Where do we go from here? Biol Psychiatry 2012;72(7):537-47
20. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-Aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry 2006;63(8):856-64
21. Mathews DC, Henter ID, Zarate CA Jr. Targeting the glutamatergic system to treat major depressive disorder: Rationale and progress to date. Drugs 2012;72(10):1313-33
22. Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-d-Aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(4):1155-9
23. Phelps LE, Brutsche N, Moral JR, et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-Aspartate antagonist. Biol Psychiatry 2009;65(2):181-4
24. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-Aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67(8):793-802
25. Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamines antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry 2012;71(11):939-46
26. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatmentresistant depression. Biol Psychiatry 2009;66(5):522-6
27. DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-Aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010;71(12):1605-11
28. Sanacora G, Smith MA, Pathak S, et al. Lanicemine: A low-Trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 2013. [Epub ahead of print]
29. Krystal JH, Sanacora G, Duman RS. Rapid-Acting glutamatergic antidepressants: The path to ketamine and beyond. Biol Psychiatry 2013;73(12):1133-41
30. Blier P, Zigman D, Blier J. On the safety and benefits of repeated intravenous injections of ketamine for depression. Biol Psychiatry 2012;72(4):e11-12
31. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-Term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013;74(4):250-6
32. Shiroma PR, Johns B, Kuskowski M, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 2014;155(1):123-9
33. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17(8):2921-7
34. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007;27(43):11496-500
35. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329(5994):959-64
36. Duman RS, Li N, Liu RJ, et al. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012;62(1):35-41
37. Jernigan CS, Goswami DB, Austin MC, et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(7):1774-9
38. Chandran A, Iyo AH, Jernigan CS, et al. Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress. Prog Neuropsychopharmacol Biol Psychiatry 2013;40(1):240-5
39. Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011;475(7354):91-6
40. Workman ER, Niere F, Raab-Graham KF. mTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling. Neuropharmacology 2013;73:192-203
41. Müller HK, Wegener G, Liebenberg N, et al. Ketamine regulates the presynaptic release machinery in the hippocampus. J Psychiatr Res 2013;47(7):892-9
42. Bonanno G, Giambelli R, Raiteri L, et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005;25(13):3270-9
43. Barbiero VS, Giambelli R, Musazzi L, et al. Chronic antidepressants induce redistribution and differential activation of acaM kinase II between presynaptic compartments. Neuropsychopharmacology 2007;32(12):2511-19
44. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: Clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 2009;9(3):197-204
45. Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depression. Prog Neurobiol 2013;100(1):15-29
46. Ishikawa M, Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J Receptor Ligand Channel Res 2010;3:25-36
47. Kotermanski SE, Johnson JW. Mg 2+imparts NMDA receptor subtype selectivity to the Alzheimers drug memantine. J Neurosci 2009;29(9):2774-9
48. Murck H. Ketamine, magnesium and major depression-From pharmacology to pathophysiology and back. J Psychiatr Res 2013;47(7):955-65
49. Lima-Ojeda JM, Vogt MA, Pfeiffer N, et al. Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brain. Prog Neuropsychopharmacol Biol Psychiatry 2013;45:28-33
50. Serafini G, Pompili M, Innamorati M, et al. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression. Curr Pharm Des 2013;19(10):1898-922
51. Preskorn SH, Baker B, Kolluri S, et al. An Innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective n-methyl-daspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008;28(6):631-7
52. Ibrahim L, Diazgranados N, Jolkovsky L, et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 2012;32(4):551-7
53. Chen J, Graham S, Moroni F, Simon R. A study of the dose dependency of a glycine receptor antagonist in focal ischemia. J Pharmacol Exp Ther 1993;267(2):937-41
54. Zhu WL, Wang SJ, Liu MM, et al. Glycine site N-methyl-D-Aspartate receptor antagonist 7-CTKA produces rapid antidepressant-like effects in male rats. J Psychiatry Neurosci 2013;38(5):306-16
55. Li N, Liu RJ, Dwyer JM, et al. Glutamate N-methyl-D-Aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011;69(8):754-61
56. Bradley CA, Peineau S, Taghibiglou C, et al. A pivotal role of GSK-3 in synaptic plasticity. Front Mol Neurosci 2012;5:13
57. Zhang XL, Sullivan JA, Moskal JR, Stanton PK. A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology 2008;55(7):1238-50
58. Burgdorf J, Zhang XL, Weiss C, et al. The N-methyl-d-Aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol Aging 2011;32(4):698-706
59. Burgdorf J, Zhang XL, Nicholson KL, et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 2013;38(5):729-42
60. Moskal JR, Kuo AG, Weiss C, et al. GLYX-13: A monoclonal antibodyderived peptide that acts as an N-methyl-D-Aspartate receptor modulator. Neuropharmacology 2005;49(7):1077-87
61. Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of a-Amino-3-hydroxy-5-methylisoxazole- 4-propionic acid receptors. Biol Psychiatry 2008;63(4):349-52
62. Moskal JR, Burch R, Burgdorf JS, et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs 2014;23(2):243-54
63. Heresco-Levy U, Gelfin G, Bloch B, et al. A randomized add-on trial of highdose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 2013;16(3):501-6
64. Zarate CA Jr, Mathews D, Ibrahim L, et al. A randomized trial of a lowtrapping nonselective N-methyl-Daspartate channel blocker in major depression. Biol Psychiatry 2013;74(4):257-64
65. Mealing GAR, Lanthorn TH, Small DL, et al. Structural modifications to an Nmethyl-D-Aspartate receptor antagonist result in large differences in trapping block. J Pharmacol Exp Ther 2001;297(3):906-14
66. Zhang JC, Li SX, Hashimoto K. R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 2014;116:137-41
67. Paul R, Schaaff N, Padberg F, et al. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: Report of two cases. World J Biol Psychiatry 2009;10(3):241-4
68. Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: A case series. Pharmacopsychiatry 2010;43(1):33-5
69. Sanderson TM, Collingridge GL, Fitzjohn SM. Differential trafficking of AMPA receptors following activation of NMDA receptors and mGluRs. Mol Brain 2011;4(1):30
70. Unoki T, Matsuda S, Kakegawa W, et al. NMDA receptor-mediated PIP5K activation to produce PI(4,5)P2 is essential for AMPA receptor endocytosis during LTD. Neuron 2012;73(1):135-48
71. Svenningsson P, Bateup H, Qi H, et al. Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. Eur J Neurosci 2007;26(12):3509-17
72. Svenningsson P, Tzavara ET, Witkin JM, et al. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA 2002;99(5):3182-7
73. Du J, Gray NA, Falke CA, et al. Modulation of synaptic plasticity by antimanic agents: The role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci 2004;24(29):6578-89
74. Du J, Creson TK, Wu LJ, et al. The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci 2008;28(1):68-79
75. Dybala M, Siwek A, Poleszak E, et al. Lack of NMDA-AMPA interaction in antidepressant-like effect of CGP 37849, an antagonist of NMDA receptor, in the forced swim test. J Neural Transm 2008;115(11):1519-20
76. Akinfiresoye L, Tizabi Y. Antidepressant effects of AMPA and ketamine combination: Role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology (Berl) 2013;230(2):291-8
77. Farley S, Apazoglou K, Witkin JM, et al. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int J Neuropsychopharmacol 2010;13(9):1207-18
78. Wolak M, Siwek A, Szewczyk B, et al. Involvement of NMDA and AMPA receptors in the antidepressantlike activity of antidepressant drugs in the forced swim test. Pharmacol Rep 2013;65(4):991-7
79. Nations KR, Bursi R, Dogterom P, et al. Maximum tolerated dose evaluation of the AMPA modulator org 26576 in healthy volunteers and depressed patients: A summary and method analysis of bridging research in support of phase II dose selection. Drugs R D 2012;12(3):127-39
80. Nations KR, Dogterom P, Bursi R, et al. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: An exploratory, randomized, double-blind, placebocontrolled trial. J Psychopharmacol 2012;26(12):1525-39
81. Du J, Suzuki K, Wei Y, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: Relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007;32(4):793-802
82. DallIgna OP, Bobermin LD, Souza DO, Quincozes-Santos A. Riluzole increases glutamate uptake by cultured C6 astroglial cells. Int J Dev Neurosci 2013;31(7):482-6
83. Takahashi K, Murasawa H, Yamaguchi K, et al. Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression. Behav Brain Res 2011;216(1):46-52
84. Banasr M, Chowdhury GMI, Terwilliger R, et al. Glial pathology in an animal model of depression: Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamatemodulating drug riluzole. Mol Psychiatry 2010;15(5):501-11
85. Li N, He X, Zhang Y, et al. Brain-derived neurotrophic factor signalling mediates antidepressant effects of lamotrigine. Int J Neuropsychopharmacol 2011;14(8):1091-8
86. Abelaira HM, Réus GZ, Ribeiro KF, et al. Lamotrigine treatment reverses depressive-like behavior and alters BDNF levels in the brains of maternally deprived adult rats. Pharmacol Biochem Behav 2012;101(3):348-53
87. Gabriel A. Lamotrigine adjunctive treatment in resistant unipolar depression: An open, descriptive study. Depress Anxiety 2006;23(8):485-8
88. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000;61(11):841-50
89. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65(3):432-41
90. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20(6):607-14
91. Normann C, Hummel B, Schärer LO, et al. Lamotrigine as adjunct to paroxetine in acute depression: A placebocontrolled, double-blind study. J Clin Psychiatry 2002;63(4):337-44
92. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003;64(4):403-7
93. Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: A randomized, placebocontrolled, double-blind study. Prim Care Companion J Clin Psychiatry 2008;10(3):187-90
94. Barbee JG, Thompson TR, Jamhour NJ, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatmentrefractory unipolar depression. J Clin Psychiatry 2011;72(10):1405-12
95. Zarate CA Jr, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004;161(1):171-4
96. Brennan BP, Hudson JI, Jensen JE, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010;35(3):834-46
97. Ibrahim L, Diazgranados N, Franco-Chaves J, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs Add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012;37(6):1526-33.